

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

VOLUNTARY ANNOUNCEMENT

This is a voluntary announcement made by Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “Company”).

The Company noticed that there is media reporting alleging that the replicated “Viagra” of the Company will soon be available in the market. The Company hereby provides information as follows:

1. the Company obtained new drug certificates for “Sildenafil Citrate” active pharmaceutical ingredients and tablets in 2003, certificate numbers of which are “Guo Yao Zheng Zi H20030493” and “Guo Yao Zheng Zi H20030494”;
2. after checking the website of the Administrative Processing Center of the China Food and Drug Administration (“CFDA Administrative Processing Centre”), the “processing status” of the production approval documents of “Sildenafil Citrate” tablets submitted by the Company has been updated to “Approval completed – Certificates to be prepared” at 09:08 on 30 July 2014. According to the explanation on the CFDA Administrative Processing Centre’s website, the status of “Approval completed – Certificates to be prepared” means the CFDA Administrative Processing Centre is preparing the approval documents (the issue version of the National Medicine Standard is prepared by the Chinese Pharmacopoeia Commission);
3. after checking the website of CFDA Administrative Processing Centre, the “processing status” of the production approval documents of “Sildenafil Citrate” active pharmaceutical ingredients submitted by the Company has been updated to “Approval in process” at 14:31 on 9 June 2014. According to the explanation on the CFDA Administrative Processing Centre’s website, the status of “Approval in process” means the China Food and Drug Administration is processing the approval;

4. the Company owns the trademark of “Jinge” the registration numbers of which are “1533743”, “4894150” and “4894151”, the certified uses of which are in products such as human drugs, medical preparations, chemical drug preparations and active pharmaceutical ingredients. After the production registration approval documents for active pharmaceutical ingredients and tablets have been obtained, the Company will carry out the relevant works as soon as possible so that the production and launching of the “Sildenafil Citrate” under the name of “Jingge” can be achieved as early as possible.

The Company will closely monitor the progress of the event and will perform its disclosure obligations on a timely basis in accordance with relevant rules and regulations.

The Company wishes to inform the investors that the Company’s designated media for publication of its information include Shanghai Securities News (上海證券報), Securities Times (證券時報), China Securities Journal (中國證券報), Securities Daily (證券日報), the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and the website of The Stock Exchange of Hong Kong Limited (<http://www.hkex.com.hk>). Investors are advised to take due care in investment and be aware of the relevant risks.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 31 July 2014

As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong, Mr. Wu Changhai and Mr. Wang Wenchu as executive directors, and Mr. Wong Lung Tak Patrick, Mr. Qiu Hongzhong, Mr. Fang Shuting and Mr. Chu Xiaoping as independent non-executive directors.